Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
AssigneeSequoia Sciences, Inc.
InventorsGary Eldridge, Steven M Martin
Life of this patent
Estimating the term…
Abstract
This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.
Claims30
A composition comprising:
- one or more of the following compounds:
- or pharmaceutically acceptable salts thereof;
- phosphatidylcholine;
- and,
- a citrate buffer from about 10 mM to about 50 mM, and wherein the composition contains less than 30 mM NaCl, and is stable when exposed to a range of temperature from 19° C. to 25° C. for 60 or more days.
A composition comprising:
- one or more of the following compounds:
- or pharmaceutically acceptable salts thereof;
- phosphatidylcholine;
- and,
- a citrate buffer from about 10 mM to about 50 mM, and wherein the composition contains less than 30 mM NaCl, and is stable when exposed to a range of temperature from 19° C. to 25° C. for 60 or more days.
A vaccine composition comprising:
- an adjuvant formulation;
- and, an effective amount of an antigen, wherein the adjuvant formulation comprises an effective amount of one or more of the following compounds:
- or pharmaceutically acceptable salts thereof;
- phosphatidylcholine;
- and,
- a citrate buffer from about 10 mM to about 50 mM.
Dependencies are inferred from the claim text.